• Skip to main content

Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

  • How To Publish
  • How to Write Plain Language Summaries
  • Frequently Asked Questions
  • Publications
    • Animated Videos
    • Bladder, Kidney and Genitals
    • Brain and Nerves
    • Cancer
    • Diabetes and Metabolic Hormones
    • Eyes and Vision
    • Heart and Circulation
    • Infections
    • Inflammatory and Immune-related disorders
    • Mental Health
    • Muscle and Bone
    • Rare Diseases
    • Skin
    • Vaccines
  • Advisory Panel
  • Supporters
  • Blog
  • About Us
  • Contact Us

Nov 25 2022

Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?

This plain language summary provides an overview of a real-world study using data from the Veterans Health Administration to look at the survival of Black men vs White men with advanced prostate cancer who are treated with two treatments, abiraterone or enzalutamide.

Read the full article here.

The original article on which this summary is based is called ‘Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer’ and was originally published in the journal Prostate Cancer and Prostatic Diseases . The original article can be read here.

  • Share on Twitter Share on Twitter
  • Share on Facebook Share on Facebook
  • Share on LinkedIn Share on LinkedIn

Written by Joanne Walker · Categorized: Bladder, Kidney and Genitals, Cancer · Tagged: abiraterone, advanced prostate cancer, enzalutamide, lay summary, metastatic castration-resistant prostate cancer, plain language summary, veterans health administration

Copyright © 2023 · Plain Language Summaries · Terms and Conditions · Privacy Policy ·